Actualización en Aspergilosis con énfasis en Aspergilosis invasora

Información del artículo

Resumen

El género Aspergillus es ubicuo en la naturaleza y de distribución universal. Por esta razón, el contacto con este hongo incluye hospederos inmunocompetentes e inmunosuprimidos. La vía aérea es la forma más frecuente de adquirir este hongo y sus manifestaciones clínicas y localización topográfica se relacionan con la interacción del hongo y la capacidad inmunológica del hospedero. La principal manifestación clínica de este hongo es a nivel respiratorio, con un impacto muy importante en mortalidad y morbilidad, especialmente en el paciente inmunosuprimido. Los pacientes con tumores hematológicos, trasplantes de corazón, pulmón y con sida son más susceptibles de presentar invasión tisular y vascular por este hongo, que en tales casos se manifiesta como Aspergilosis Invasora (AI). La AI ofrece dificultades diagnósticas en el hospedero inmunosuprimido por lo que en este grupo de pacientes el uso de métodos de diagnóstico no invasores permite guiar el abordaje terapéutico. En la actualidad se dispone de medicamentos antifúngicos del grupo de los azoles (voriconazol) y de las equinocandinas (caspofungina) que han mejorado el resultado de la AI. En este artículo se actualiza la literatura en cuanto al diagnóstico y tratamiento de la AI.

Palabras Claves:

Aspergilosis Invasora

inmunosupresión

diagnóstico

tratamiento

Abstract

The genus Aspergillus is ubiquitous in nature and has universal distribution; for this reason contact with this fungus includes immunocompetent and non-immunocompetent hosts. The most common form of acquiring this fungus is through air, and its clinical manifestations and topographic location correspond to the interaction of the fungus and its host's immune capacity. The main clinical manifestation of this fungus is a breathing condition and has a very significant impact on mortality and morbidity, especially in non-immunocompetent patients. Patients with haematological malignancies, heart or lung transplant surgeries, and AIDS are the most susceptible to present tissue and vascular invasion by this fungus in the form of invasive aspergillosis (IA). The IA presents diagnostic difficulties in non-immunocompetent hosts; therefore using non-invasive diagnosis methods for this group of patients offers therapeutic approach guidance. Antifungal drugs such as azoles (voriconazole) and echinocandins (caspofungin), that have improved the AI group results, are available nowadays. This article updates the literature on AI diagnosis and treatment.

Keyword:

Invasive Aspergillosis

non-immunecompetent

diagnosis

treatment

El Texto completo está disponible en PDF

Referencias

[1.]

T. Patterson.

Aspergillus species.

Principles and practice of infectious diseases., 7th, pp. 3241-3256

[2.]

G. Maschmeyer, A. Haas, O.A. Cornely.

Invasive aspergilosis.

Drugs, 67 (2007), pp. 1567-1701

Medline

[3.]

P.E. Verwij, M.E. Brandt.

Aspergillus, Fusarium, and other opportunistic monilliaceous fungi.

Manual of clinical microbiology,, 9th, pp. 1802-1838

[4.]

T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, K.A. Marr, et al.

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America.

CID, 46 (2008), pp. 327-360

[5.]

T.F. Patterson.

Aspergillosis.

Clinical micology., 1st, pp. 221-240

[6.]

R. Sherif, B.H. Segal.

Pulmonary aspergilosis: clinical presentation, diagnostic test, management and complications.

Curr Opin Pulm Med, 16 (2010), pp. 242-250

http://dx.doi.org/10.1097/MCP.0b013e328337d6de | Medline

[7.]

P.D. Barnes, K.A. Marr.

Aspergillosis: spectrum of diseases, diagnosis and treatment.

Infect Dis Clin N Am, 20 (2006), pp. 545-561

[8.]

G.R. Thompson III, T.F. Patterson.

Pulmonary Aspergillosis.

Semin Respir Crit Care Med, 29 (2008), pp. 103-110

http://dx.doi.org/10.1055/s-2008-1063849 | Medline

[9.]

M.D. Richardson, W. Hope.

Aspergillus.

Clinical Micology, 2th, pp. 271-296

[10.]

B.H. Segal.

Aspergillosis.

N Engl J Med, 360 (2009), pp. 1870-1884

http://dx.doi.org/10.1056/NEJMra0808853 | Medline

[11.]

M. Tumbarello, E. Tacconelli, L. Pagano, et al.

Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection.

J Infect, 34 (1997), pp. 55-60

Medline

[12.]

Y. Nivoix, M. Velten, V. Letscher-Bru, et al.

Factors associated with overall and attributable mortality in invasive aspergillosis.

CID, 47 (2008), pp. 1176-1184

[13.]

W.W. Hope, T.J. Wals, D.W. Denning.

Laboratory diagnosis of invasive aspergillosis.

Lancet Infect Dis, 5 (2005), pp. 609-622

http://dx.doi.org/10.1016/S1473-3099(05)70238-3 | Medline

[14.]

Clinical Mycology, 2th,

[15.]

J. Pontón.

Diagnostico Microbiológico de las micosis.

Rev Iberoam Micol, 19 (2002), pp. 25-29

Medline

[16.]

R. Christopher.

Thornton. Detection of Invasive Aspergillosis.

Academic Press, (2010), pp. 188-216

[17.]

Cuervo SI, Rivas P, Sánchez R, Cortés JE. Epidemiología, susceptibilidad antimicótica y factores de riesgo de mortalidad de fungemia no candida en pacientes con cáncer. En prensa 2010.

[18.]

Rivas P, Cuervo SI, Sanchez R. Tendencia en la frecuencia y susceptibilidad in vitro a agentes antifúngicos de aislamientos de hongos diferentes a Candida spp. a partir de hemocultivos en pacientes con Cáncer (1999-2009). En prensa. 2010.

[19.]

J. Maertens, K. Theunissen, T. Lodewyck, K. Lagrou, J. Van Eldere.

Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders.

Mycoses, 50 (2007), pp. 2-17

http://dx.doi.org/10.1111/j.1439-0507.2007.01423.x | Medline

[20.]

M.A. Mennink-Kersten, J.P. Donnelly, P.E. Verweij.

Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Lancet Infect Dis, 4 (2004), pp. 349-357

http://dx.doi.org/10.1016/S1473-3099(04)01045-X | Medline

[21.]

Gutierrez GP, Rivas P, Cuervo S, Sánchez R, Parra C. Valor diagnóstico del galactomanano y proteína C reactiva en pacientes con neoplasia hematolinfoide y neutropenia con factor de riesgo de aspergilosis invasiva. En prensa 2010.

[22.]

S. Fah Yeo, B. Wong.

Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections.

Clin Microbiol. Rev, 15 (2002), pp. 465-484

Medline

[23.]

L. Millon, R. Piarroux, E. Deconinck, C.E. Bulabois, F. Grenouillet, P. Rohrlich, J.M. Costa, S. Bretagne.

Use of Real-Time PCR To Process the First Galactomannan-Positive Serum Sample in Diagnosing Invasive Aspergillosis.

J. Clin. Microbiol, 43 (2005), pp. 5007-5101

[24.]

España PP. Diagnóstico de Aspergilosis pulmonar invasiva y semiinvasiva. (en línea). (Consultado 23 junio. 2010) Disponible en: www.svnpar.com.

[25.]

J. Mesa, P. Rivas, S.I. Cuervo, M. Mejía.

Diagnóstico histopatológico de micosis invasivas en el paciente inmunocomprometido del Instituto Nacional de Cancerología, en Bogotá.

Rev Colomb Cancerol, 10 (2006), pp. 207-211

[26.]

British Committee for Standards in Haematology. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. Writing group: Prentice AG, Glasmacher A, Hobson RP, Schey S, Barnes RA, Donnelly JP, et al. London: 2007.

[27.]

D.L. Klein, G. Gamsu.

Thoracic Manifestations of Aspergillosis.

AJR, 134 (1980), pp. 543-552

http://dx.doi.org/10.2214/ajr.134.3.543 | Medline

[28.]

J.E. Kuhlman, E.K. Fishman, S.S. Siegelman.

Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis.

Radiology, 157 (1985), pp. 611-614

http://dx.doi.org/10.1148/radiology.157.3.3864189 | Medline

[29.]

J.E. Kuhlman, E.K. Fishman, P.A. Burch, J.E. Karp, E.A. Zerhouni, S.S. Siegelman.

Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management.

Chest, 92 (1987), pp. 95-99

Medline

[30.]

N.C. Hsu, W.J. Lee, S.W. Kuo, J.S. Jerng.

Halos and Crescents.

Am J Med, 122 (2009), pp. 738-740

http://dx.doi.org/10.1016/j.amjmed.2009.04.010 | Medline

[31.]

R.H. Hruban, M.A. Meziane, E.A. Zerhouni, P.S. Wheeler, J.S. Dumler, G.M. Hutchins.

Radiologic-pathologic correlations of the CT halo sign in invasive pulmonary aspergillosis.

J Comput Assist Tomogr, 11 (1987), pp. 534-536

Medline

[32.]

D. Caillot, J.F. Cauaillier, A. Bernard, O. Casasnovas, D.W. Denning, L. Mannone, et al.

Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.

J Clin Oncol, 19 (2001), pp. 253-259

http://dx.doi.org/10.1200/jco.2001.19.1.253 | Medline

[33.]

F. Reichenberger, J.M. Habicht, A. Gratwohl, M. Tamm.

Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients.

Eur Respir J, 19 (2002), pp. 743-755

Medline

[34.]

R. Greene.

The radiological spectrum of pulmonary aspergillosis.

Med Mycol, 43 (2005), pp. S147-S154

Medline

[35.]

H.J. Won, K.S. Lee, J.E. Cheon, J.H. Hwang, T.S. Kim, H.G. Lee, et al.

Invasive pulmonary aspergillosis: prediction at thin-section CT in patients with neutropenia--a prospective study.

Radiology, 208 (1998), pp. 777-782

http://dx.doi.org/10.1148/radiology.208.3.9722859 | Medline

[36.]

M. Kami, Y. Tanaka, Y. Kanda, S. Ogawa, T. Masumoto, K. Ohtomo, et al.

Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients.

Haematologica, 85 (2000), pp. 745-752

Medline

[37.]

T. Yeghen, C. Kibbler, H.G. Prentice, L.A. Berger, R.K. Wallesby, P.H. McWhinney, et al.

Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution.

Clin Infect Dis, 31 (2000), pp. 859-868

http://dx.doi.org/10.1086/318133 | Medline

[38.]

B. De Pauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, T. Calandra, et al.

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

CID, 46 (2008), pp. 1813-1821

[39.]

J. Maertens, P. Frére, C. Lass-Flörl, W. Heinz, O. Cornely.

Antifungal prophylaxis in leukemia patients 2009 update of the ECIL 1 and 2 guidelines.

3rd European Conference on Infection in Leukemia, pp. 25-26

[40.]

O. Marchetti, C. Cordonier, Th. Calandra.

Empirical antifungal therapy in neutropaenic cancer patients with persistent fever.

Europ J of Cancer, (2007), pp. 32-42

[41.]

J. Maertens, K. Theunissen, G. Verhoef.

Galactomannan and computed tomography-based preemptive antifungal theraphy in nuetropenic patients at high risk for invasive fungal infection: a prospective feasible study.

CID, 41 (2005), pp. 1242-1250

[42.]

C. Cordonier, C. Pautas, S. Maury.

Empirical versus preemptive antifungal therapy for high-risk febrile neutropenic patients: a randomized, controlled trial.

CID, 48 (2009), pp. 1042-1051

[43.]

National Comprehensive Cancer Network. Prevention and treatment of cancer related Infections. (en línea) 2009. (Consultado 1 de marzo de 2010). Disponible en: www.nccn.org.

Indexada en:

Síguenos:

Indexada en:

Síguenos:

Suscríbase a la newsletter